

**Consolidated Financial Statements for the Third Quarter Ended December 31, 2016
FY2017 (April 1, 2016 - March 31, 2017) [UNAUDITED]**

Company name: Takara Holdings Inc.
 Stock exchange listings: Tokyo Stock Exchange (1st section)
 Code number: 2531
 URL: <http://www.takara.co.jp/>
 Company representative: Toshio Kakimoto, President
 Contact: Takuya Kakemi, General Manager of Investor Relations Dept.
 TEL : (075)241-5124
 Quarterly statement filing date (as planned): February 10, 2017

- Notes: 1. The accompanying financial statements have been prepared in accordance with accounting principles and practices generally accepted in Japan.
 2. Amounts are rounded down to the nearest million yen.

1. Results for the nine months ended December 31, 2016 (April 1, 2016 – December 31, 2016)

(1) Operating results

Note: Percentages indicated changes from the same period of the previous fiscal year.

| | Nine months ended December 31, 2016 | | Nine months ended December 31, 2015 | |
|--|--|--------|--|--------|
| | (Millions of yen) | (%) | (Millions of yen) | (%) |
| Net sales | 172,218 | 1.2 | 170,250 | 2.5 |
| Operating income(loss) | 12,741 | 26.3 | 10,091 | (4.6) |
| Ordinary income(loss) | 13,403 | 23.4 | 10,858 | (1.0) |
| Net income (loss) attributable to owners of the parent | 8,876 | 35.6 | 6,546 | 9.4 |
| Net income (loss) per share (Yen) | 44.11 | | 32.53 | |
| Fully diluted net income per share (Yen) | - | | - | |
| Note: Comprehensive income | 1,558 | (66.7) | 4,679 | (47.6) |

(2) Financial position

| | As of December 31, 2016 | As of March 31, 2016 |
|--------------------|-------------------------|----------------------|
| | (Millions of yen) | (Millions of yen) |
| Total assets | 269,737 | 253,253 |
| Net assets | 158,981 | 156,148 |
| Equity ratio (%) | 48.3 | 51.5 |
| (Reference) Equity | 130,334 | 130,386 |

2. Dividends

| | Dividend per share (Yen) | | |
|--------------------|------------------------------|-------------------------------|--|
| | Year ended March 31, 2016 | Year ending March 31, 2017 | Year ending March 31, 2017 (Forecast) |
| First quarter end | - | - | - |
| Second quarter end | - | - | - |
| Third quarter end | - | - | - |
| Year end | 12.00 | | 13.00 |
| Annual | 12.00 | | 13.00 |

Notes: Correction of dividend forecast from the most recent dividend forecast : Yes
 The year-end dividend for FY2016 included a commemorative dividend of ¥1.00

3. Forecast for the year ending March 31, 2017 (April 1, 2016 – March 31, 2017)

Note: Percentages indicated changes from the same period of the previous fiscal year.

| | Year ending March 31, 2017 | |
|--|----------------------------|------|
| | (Millions of yen) | (%) |
| Net sales | 234,100 | 3.9 |
| Operating income(loss) | 13,100 | 12.1 |
| Ordinary income(loss) | 13,800 | 7.5 |
| Net income (loss) attributable to owners of the parent | 8,300 | 17.6 |
| Net income (loss) per share (Yen) | 41.25 | |

Note: Correction of financial forecast from the most recent financial forecast : Yes

4. Others

- (1) Material changes in subsidiaries during this period
(Changes in scope of consolidations resulting from change in specific subsidiaries) : No
- (2) Applying of specific accounting treatments of the quarterly consolidated financial statements : No
- (3) Changes in accounting policies, changes in accounting estimates, and retrospective restatement
 - 1) Changes based on revisions of accounting standard : Yes
 - 2) Changes other than ones based on revisions of accounting standard : No
 - 3) Changes in accounting estimates : No
 - 4) Restatement : No
- (4) Number of outstanding shares (common stock)
 - 1) Number of outstanding shares at year end (Treasury stocks are included)
 - As of December 31, 2016 : 217,699,743
 - As of March 31, 2016 : 217,699,743
 - 2) Number of treasury stocks at year end
 - As of December 31, 2016 : 16,475,585
 - As of March 31, 2016 : 16,475,391
 - 3) Average number of outstanding shares
 - Nine months ended December 31, 2016 : 201,224,286
 - Nine months ended December 31, 2015 : 201,225,138

Contents of the attached document

| | | |
|----|---|----|
| 1. | Qualitative Information for the Nine Months Ended December 31, 2016 ----- | 2 |
| | (1) Consolidated Financial Results ----- | 2 |
| | (2) Consolidated Financial Position ----- | 3 |
| | (3) Qualitative Information Regarding Consolidated Forecasts ----- | 3 |
| 2. | Summary Information (Notes) ----- | 4 |
| | (1) Change in Accounting Policies and Changes and Retrospective Restatement of Accounting Estimates---- | 4 |
| | (2) Additional Information----- | 4 |
| 3. | Consolidated Quarterly Financial Statements ----- | 5 |
| | (1) Consolidated Quarterly Balance Sheets ----- | 5 |
| | (2) Consolidated Quarterly Statements of Income and Consolidated Quarterly Statements of Comprehensive Income ----- | 7 |
| | Consolidated Quarterly Statements of Income (For the Nine Months Ended December 31, 2016 and 2015) ----- | 7 |
| | Consolidated Quarterly Statements of Comprehensive Income (For the Nine Months Ended December 31, 2016 and 2015) ----- | 8 |
| | (3) Notes on Consolidated Quarterly Financial Statements ----- | 9 |
| | (Notes on Premise of Going Concern) ----- | 9 |
| | (Notes on Material Changes in Shareholders' Equity) ----- | 9 |
| | (Segment Information) ----- | 9 |
| | (Significant Subsequent Events) ----- | 10 |
| o | Supplement for the Consolidated Quarterly Financial Statements | |

1. Qualitative Information for the Nine Months Ended December 31, 2016

(1) Consolidated Financial Results

In the nine months ended December 31, 2016, although the Japanese economy maintained a moderate recovery as the hiring and income environment improved, personal spending remained weak.

On the other hand, overseas, while the American economy continued on a recovery path, there was continued uncertainty for the future of the global economy caused by the downside risk in emerging country economies, the Brexit issue in the U.K., the impact of future policies in the U.S. and other issues.

Under these economic circumstances, moving into the final fiscal year of the Takara Group Medium-Term Management Plan FY2017, which is the second step of efforts toward achieving the Takara Group Vision 2020, our long-term vision, the Group continued to make efforts to improve domestic business profitability and to expand and grow our overseas business while working on steady business activities with aim of transforming into a well-balanced business structure that can hold up well to business environment changes by accelerating growth in our Biomedical Business.

As a result, in the nine months ended December 31, 2016, net sales were up by 1.2% year on year to ¥172,218 million. Gross profit rose 4.4% year on year to ¥70,881 million. Operating income increased by 26.3% year on year to ¥12,741 million while ordinary income rose 23.4% year on year to ¥13,403 million. Net income attributable to owners of the parent increased by 35.6% year on year to ¥8,876 million.

Results by business segment were as follows.

[Takara Shuzo Group]

For alcoholic beverages, in the nine months ended December 31, 2016, while sales of shochu declined year on year, sake sales were flat compared with the same period of the previous fiscal year. Sales of light-alcohol refreshers increased as sales of Takara Shochu High Ball remained robust.

As sales of other alcoholic beverages such as whiskey also rose, sales of alcoholic beverages overall increased.

In the Seasonings Business, sales increased due to healthy sales of mirin and cooking sake. Sales of raw alcohol, etc. also increased, whereas transportation sales declined.

In the Japanese Food Wholesale Business in overseas markets, sales grew as businesses at FOODEX S.A.S. (France), Cominport Distribución S.L. (Spain), and others remained buoyant.

As a result, net sales for the Takara Shuzo Group rose 1.3% year on year to ¥148,818 million. Cost of sales increased by 0.2% to ¥92,152 million. Consequently, gross profit rose 3.3% year on year to ¥56,666 million. SG&A expenses were up by 1.0% year on year to ¥47,252 million due to the increases in promotion expenses and transportation expenses.

Accordingly, the Takara Shuzo Group recorded operating income up 16.4% year on year to ¥9,413 million in the nine months ended December 31, 2016.

[Takara Bio Group]

Net sales for the nine months ended December 31, 2016 decreased by 0.3% year on year to ¥20,645 million despite increased sales on a local currency basis overseas, reflecting the stronger Japanese yen. Cost of sales decreased by 11.9% year on year to ¥8,106 million as the cost rate fell due to changes in the structure of sales for each product and other factors. Consequently, gross profit increased by 9.0% year on year to ¥12,538 million. SG&A expenses decreased by 2.5% year on year to ¥9,813 million due to the declines in research and development expenses and other expenses. As a result, the Takara Bio Group recorded operating income up 88.6% year on year to ¥2,724 million in the nine months ended December 31, 2016.

[Takara Healthcare]

Net sales for the nine months ended December 31, 2016 fell by 2.8% year on year to ¥1,337 million due to falling sales of OEM cosmetics. Cost of sales was down by 21.5% year on year to ¥510 million. Consequently, gross profit increased by 13.9% year on year to ¥826 million. SG&A expenses were up by 18.7% year on year to ¥813 million, mainly due to the increases in promotion expenses and administrative expenses. As a result, Takara Healthcare's operating income decreased by 67.8% year on year to ¥13 million.

[Other]

Net sales of business segments other than the reported segments for the nine months ended December 31, 2016 increased by 2.2% year on year to ¥4,465 million. Cost of sales increased by 0.5% year on year to ¥3,857 million. Consequently, gross profit increased by 14.4% year on year to ¥608 million. SG&A expenses were up by 0.3% year on year to ¥501 million. As a result, operating income grew by 231.1% year on year to ¥107 million.

Breakdown of sales results by product category

| Segment | Equivalent Period of Previous Fiscal Year (From April 1, 2015, to December 31, 2015) | Period under Review (from April 1, 2016, to December 31, 2016) | YoY Comparison |
|--|--|--|-------------------|
| Product category | Amount (Millions of yen) | Amount (Millions of yen) | (%) |
| Takara Shuzo Group | | | |
| Shochu | 45,539 | 44,569 | 97.9 |
| Sake | 19,848 | 19,855 | 100.0 |
| Light-alcohol refreshers | 21,263 | 23,698 | 111.5 |
| Other alcoholic beverages | 10,458 | 10,592 | 101.3 |
| Alcoholic beverages total | 97,110 | 98,716 | 101.7 |
| <i>Hon Mirin</i> | 11,933 | 11,987 | 100.4 |
| Other seasonings | 7,199 | 7,603 | 105.6 |
| Seasonings total | 19,133 | 19,590 | 102.4 |
| Raw alcohol, etc. | 5,432 | 5,667 | 104.3 |
| Transportation | 8,922 | 8,039 | 90.1 |
| Japanese food wholesales business in overseas markets | 15,164 | 15,759 | 103.9 |
| Other | 1,096 | 1,044 | 95.3 |
| Total | 146,859 | 148,818 | 101.3 |
| Takara Bio Group | 20,706 | 20,645 | 99.7 |
| Takara Healthcare | 1,376 | 1,337 | 97.2 |
| Other | 4,369 | 4,465 | 102.2 |
| Sales not allocated to business segments and intersegment transactions | (3,061) | (3,048) | - |
| Total | 170,250 | 172,218 | 101.2 |

Notes: Amounts include alcohol tax but do not include consumption tax.

(2) Consolidated Financial Position

Total assets stood at ¥269,737 million as of December 31, 2016, up by ¥16,484 million from March 31, 2016. Current assets stood at ¥172,857 million, up by ¥13,784 million. This increase primarily resulted from increases of ¥6,456 million in cash and deposits, ¥15,234 million in notes and accounts receivable-trade and ¥2,976 million in merchandise and finished goods, despite a decline of ¥11,528 million in securities.

Noncurrent assets increased by ¥2,700 million from the end of the previous fiscal year to ¥96,880 million. The main factors were increases of ¥3,854 million in property, plant and equipment and ¥833 million in investments and other assets, including investment securities, and a decrease of ¥1,988 million in intangible assets.

Total liabilities amounted to ¥110,756 million as of December 31, 2016, up by ¥13,652 million from March 31, 2016. Current liabilities rose ¥20,421 million from the end of the previous fiscal year to ¥68,069 million. This was primarily due to increases of ¥1,455 million in notes and accounts payable-trade, ¥3,010 million in short-term loans payable, ¥10,000 million in current portion of bonds and ¥4,729 million in accrued alcohol tax.

Noncurrent liabilities declined ¥6,769 million from the end of the previous fiscal year to ¥42,686 million. This was primarily due to a ¥10,000 million decrease resulting from the transfer of bonds to current liabilities, whereas long-term loans payable and other non-current liabilities including deferred tax liabilities increased by ¥1,061 million and by ¥2,073 million, respectively.

Net assets stood at ¥158,981 million as of December 31, 2016, up ¥2,832 million from the end of the previous fiscal year. The main factors were increases of ¥6,461 million in retained earnings, ¥2,777 million in valuation difference on available-for-sale securities and ¥2,884 million in non-controlling interests, and a decline of ¥9,720 million in foreign currency translation adjustment.

(3) Qualitative Information Regarding Consolidated Forecasts

The Company has revised the consolidated forecasts for the fiscal year ending March 31, 2017 released on November 10, 2016, based on consideration of business performance in the nine months ended December 31, 2016 and recent performance trends.

Consolidated net sales are unchanged from the previous forecast, as net sales for both Takara Shuzo Group and Takara Bio Group are in line with the forecast.

Meanwhile, due to the steady performance of the domestic alcoholic beverages business and the upswing in business results at overseas subsidiaries at Takara Shuzo Group, as well as Takara Bio Group's projected performance surpassing the forecast by revenues from gene therapy and other factors, income is expected to exceed the plan. Accordingly, the Company revised its forecast upwards for consolidated operating income by ¥500 million, consolidated ordinary income by ¥500 million, and net income attributable to owners of the parent by ¥100 million, respectively.

2. Summary Information (Notes)

(1) Change in Accounting Policy and Retrospective Restatement of Accounting Estimates

(Change in Accounting Policy)

(Application of Practical Solution on a change in depreciation method due to Tax Reform 2016)

In the three month period ended June 30, 2016, certain consolidated subsidiaries applied Practical Solution on a change in depreciation method due to Tax Reform 2016 (PITF No. 32, June 17, 2016) following the revision of the Corporation Tax Act, and changed the method of depreciation for structures and facilities attached to buildings acquired on and after April 1, 2016 from the declining-balance method to the straight-line method.

The impact of this change on operating income, ordinary income, and profit before income taxes and minority interests for the nine month period ended December 31, 2016 is immaterial.

(2) Additional Information

(Application of Revised Implementation Guidance on Recoverability of Deferred Tax Assets)

The Company has been applying the Revised Implementation Guidance on Recoverability of Deferred Tax Assets (ASBJ Guidance No. 26 of March 28, 2016) from the beginning of the three month period ended June 30, 2016.

3. Consolidated Quarterly Financial Statements

(1) Consolidated Quarterly Balance Sheets

(Millions of Yen)

| | As of Mar. 31, 2016 | As of Dec. 31, 2016 |
|-------------------------------------|---------------------|---------------------|
| Assets | | |
| Current assets | | |
| Cash and deposits | 38,386 | 44,843 |
| Notes and accounts receivable-trade | 53,602 | 68,837 |
| Securities | 28,238 | 16,710 |
| Merchandise and finished goods | 29,739 | 32,715 |
| Work in process | 1,077 | 1,091 |
| Raw materials and supplies | 3,401 | 3,645 |
| Other | 4,859 | 5,246 |
| Allowance for doubtful accounts | (231) | (232) |
| Total current assets | 159,073 | 172,857 |
| Noncurrent assets | | |
| Property, plant and equipment | 53,065 | 56,919 |
| Intangible assets | | |
| Goodwill | 6,975 | 5,835 |
| Other | 4,035 | 3,187 |
| Total intangible assets | 11,010 | 9,022 |
| Investments and other assets | | |
| Investment securities | 24,747 | 25,527 |
| Other | 5,468 | 5,502 |
| Allowance for doubtful accounts | (112) | (92) |
| Total investments and other assets | 30,103 | 30,937 |
| Total noncurrent assets | 94,179 | 96,880 |
| Total assets | 253,253 | 269,737 |

(Millions of Yen)

| | As of Mar. 31, 2016 | As of Dec. 31, 2016 |
|---|---------------------|---------------------|
| Liabilities | | |
| Current liabilities | | |
| Notes and accounts payable-trade | 15,201 | 16,656 |
| Short-term loans payable | 4,994 | 8,004 |
| Current portion of bonds | - | 10,000 |
| Accrued alcohol tax | 7,855 | 12,584 |
| Accrued expenses | 4,965 | 5,728 |
| Income taxes payable | 2,307 | 2,501 |
| Provision for sales promotion expenses | 1,870 | 2,264 |
| Other provision | 2,319 | 1,696 |
| Other | 8,133 | 8,633 |
| Total current liabilities | 47,648 | 68,069 |
| Noncurrent liabilities | | |
| Bonds payable | 20,000 | 10,000 |
| Long-term loans payable | 10,255 | 11,316 |
| Net defined benefit liability | 8,544 | 8,660 |
| Long-term deposits received | 5,379 | 5,358 |
| Other | 5,277 | 7,350 |
| Total noncurrent liabilities | 49,456 | 42,686 |
| Total liabilities | 97,104 | 110,756 |
| Net assets | | |
| Shareholders' equity | | |
| Capital stock | 13,226 | 13,226 |
| Capital surplus | 1,879 | 1,650 |
| Retained earnings | 113,663 | 120,125 |
| Treasury stock | (9,938) | (9,938) |
| Total shareholders' equity | 118,830 | 125,063 |
| Accumulated other comprehensive income | | |
| Valuation difference on available-for-sale securities | 6,822 | 9,600 |
| Deferred gains or losses on hedges | (445) | 223 |
| Foreign currency translation adjustment | 5,548 | (4,172) |
| Remeasurements of defined benefit plans | (370) | (380) |
| Total accumulated other comprehensive income | 11,555 | 5,271 |
| Noncontrolling interests | 25,762 | 28,646 |
| Total net assets | 156,148 | 158,981 |
| Total liabilities and net assets | 253,253 | 269,737 |

(2) Consolidated Quarterly Statements of Income and Consolidated Quarterly Statements of Comprehensive Income
(Consolidated Statements of Income)
(For the Nine Months Ended December 31, 2016 and 2015)

(Millions of Yen)

| | FY2016 (Apr. 1, 2015 – Dec. 31, 2015) | FY2017 (Apr. 1, 2016 – Dec. 31, 2016) |
|--|---|---|
| Net sales | 170,250 | 172,218 |
| Cost of sales | 102,349 | 101,336 |
| Gross profit | 67,901 | 70,881 |
| Selling, general and administrative expenses | 57,809 | 58,139 |
| Operating income | 10,091 | 12,741 |
| Non-operating income | | |
| Dividends income | 436 | 453 |
| Equity in earnings of affiliates | 275 | 242 |
| Other | 533 | 432 |
| Total non-operating income | 1,245 | 1,128 |
| Non-operating expenses | | |
| Interest expenses | 335 | 321 |
| Other | 143 | 144 |
| Total non-operating expenses | 479 | 466 |
| Ordinary income | 10,858 | 13,403 |
| Extraordinary income | | |
| Gain on sales of noncurrent assets | — | 864 |
| Other | 327 | 66 |
| Total extraordinary income | 327 | 931 |
| Extraordinary loss | | |
| Loss on sales and retirement of noncurrent assets | — | 199 |
| Loss on valuation of investment securities | 148 | 108 |
| Other | 51 | 17 |
| Total extraordinary losses | 199 | 325 |
| Income before income taxes and minority interests | 10,986 | 14,009 |
| Income taxes-current | 4,168 | 4,461 |
| Income taxes-deferred | (122) | (13) |
| Total income taxes | 4,046 | 4,448 |
| Net income | 6,940 | 9,560 |
| Net income attributable to the noncontrolling interest | 393 | 684 |
| Net income attributable to owners of the parent | 6,546 | 8,876 |

(Consolidated Quarterly Statements of Comprehensive Income)
(For the Nine Months Ended DEcember 31, 2016 and 2015)

(Millions of Yen)

| | FY2016 (Apr. 1, 2015 – Dec. 31, 2015) | FY2017 (Apr. 1, 2016 – Dec. 31, 2016) |
|--|---|---|
| Net income | 6,940 | 9,560 |
| Other comprehensive income | | |
| Valuation difference on available-for-sale securities | (56) | 2,777 |
| Deferred gains or losses on hedges | (425) | 668 |
| Foreign currency translation adjustment | (1,732) | (11,449) |
| Remeasurements of defined benefit plans | (34) | 0 |
| Share of other comprehensive income of associates accounted for using equity method | (11) | — |
| Total other comprehensive income | (2,260) | (8,002) |
| Comprehensive income | 4,679 | 1,558 |
| (Comprehensive income attributable to) | | |
| Comprehensive income attributable to owners of the parent | 4,568 | 2,592 |
| Comprehensive income attributable to noncontrolling interest | 110 | (1,033) |

(3) Notes on Consolidated Quarterly Financial Statements

(Notes on Premise of Going Concern)

No items to report.

(Notes on Material Changes in Shareholders' Equity)

No items to report.

(Segment Information)

I. Equivalent Period of Previous Fiscal Year (From April 1, 2015, to December 31, 2015)

1. Net sales and Income (Loss) by Reported Segment

(Millions of yen)

| | Reported Segment | | | | Other (Note: 1) | Total | Adjustment (Note: 2) | Amount recognized in consolidated quarterly statements of income (Note: 3) |
|-----------------------|--------------------------|---------------------|----------------------|----------|--------------------|---------|-------------------------|---|
| | Takara Shuzo Group | Takara Bio Group | Takara Healthcare | Subtotal | | | | |
| Net sales | | | | | | | | |
| External customers | 146,673 | 20,048 | 1,374 | 168,097 | 1,807 | 169,904 | 346 | 170,250 |
| Intersegment | 185 | 657 | 1 | 845 | 2,561 | 3,407 | (3,407) | - |
| Total | 146,859 | 20,706 | 1,376 | 168,942 | 4,369 | 173,311 | (3,061) | 170,250 |
| Segment income (loss) | 8,085 | 1,444 | 40 | 9,570 | 32 | 9,603 | 488 | 10,091 |

- Notes:
1. Other includes business segments that are not part of reported segments, such as the printing business and other subsidiaries.
 2. Details of adjustment amounts are as follows.
 - (1) Net sales to external customers are income from real estate rent recognized by the Company.
 - (2) Segment income comprises intersegment eliminations of ¥28 million and income of the Company not allocated to business segments of ¥459 million.
 3. Segment income has been adjusted to the operating income of consolidated quarterly statements of income.

2. Information on Impairment Loss on Noncurrent Assets, Goodwill, etc. by Reportable Segment

No items to report.

II. Period under Review (From April 1, 2016, to December 31, 2016)

1. Net sales and Income (Loss) by Reported Segment

(Millions of yen)

| | Reported Segment | | | | Other (Note: 1) | Total | Adjustment (Note: 2) | Amount recognized in consolidated quarterly statements of income (Note: 3) |
|--------------------|--------------------------|---------------------|----------------------|----------|--------------------|---------|-------------------------|---|
| | Takara Shuzo Group | Takara Bio Group | Takara Healthcare | Subtotal | | | | |
| Net sales | | | | | | | | |
| External customers | 148,648 | 20,036 | 1,335 | 170,021 | 1,851 | 171,872 | 345 | 172,218 |
| Intersegment | 169 | 608 | 1 | 779 | 2,614 | 3,394 | (3,394) | - |
| Total | 148,818 | 20,645 | 1,337 | 170,801 | 4,465 | 175,267 | (3,048) | 172,218 |
| Segment income | 9,413 | 2,724 | 13 | 12,151 | 107 | 12,259 | 482 | 12,741 |

- Notes:
1. Other includes business segments that are not part of reported segments, such as the printing business and other subsidiaries.
 2. Details of adjustment amounts are as follows.
 - (1) Net sales to external customers are income from real estate rent recognized by the Company.
 - (2) Segment income comprises intersegment eliminations of ¥65 million and income of the Company not allocated to business segments of ¥416 million.
 3. Segment income has been adjusted to the operating income of consolidated quarterly statements of income.

2. Matters concerning Changes to Reporting Segments

(Application of Practical Solution on a change in depreciation method due to Tax Reform 2016)

As stated in Change in Accounting Policy, in the three month period ended June 30, 2016, certain consolidated subsidiaries applied Practical Solution on a change in depreciation method due to Tax Reform 2016, and changed the method of depreciation for structures and facilities attached to buildings acquired on and after April 1, 2016 from the declining-balance method to the straight-line method.

The impact of this change on segment income for the nine month period ended December 31, 2016 is immaterial.

3. Information on Impairment Loss on Noncurrent Assets, Goodwill, etc. by Reportable Segment

An impairment loss of ¥199 million has been recorded in the Takara Bio Group segment.

(Significant Subsequent Events)

(Merger through share acquisition)

Takara Bio USA Holdings Inc. (“Takara Bio USA”), a wholly owned subsidiary of Takara Bio Inc., executed a merger agreement with Rubicon Genomics, Inc. (“Rubicon”) pursuant to which Takara Bio USA acquired Rubicon’s shares, making it a subsidiary, on December 15, 2016, and completed the acquisition on January 17, 2017.

(1) Purpose of the share acquisition

Takara Bio Group has been focused on the development of next generation sequencing (NGS) reagent kits, which are used in a variety of fields ranging from basic research through industrial applications. By welcoming Rubicon into Takara Bio Group, Rubicon’s sample preparation technologies for ultra-low input DNA sequencing analysis complement Takara Bio Group’s sample preparation technologies for ultra-low input RNA sequencing analysis, allowing the Group to provide a broader range of products and services in the area of ultra-low input nucleic acid analysis.

Furthermore, with the addition of preparation systems (instruments) for NGS of WaferGen Bio Systems, Inc., which is planned to be acquired by the Group in March 2017, Takara Bio Group will expand its products and services lineup across a wide range of area from basic research through industrial applications.

(2) Name of the counterparty to the share acquisition

Management and other shareholders of the company to be acquired

(3) Name, business contents and scale of the counterparty to be acquired

1) Name: Rubicon Genomics, Inc.

2) Location: 4743 Venture Drive, Ann Arbor, MI 48108 United States

3) Representative: Dr. James Koziarz, CEO

4) Business: Manufacturing and sales of research reagents

5) Operating performance and financial position of the company for the fiscal year ended December 31, 2015:

Capital: 13,249 Thousand U.S. Dollars

Net assets: (447) Thousand U.S. Dollars

Total assets: 4,338 Thousand U.S. Dollars

Net sales: 8,346 Thousand U.S. Dollars

Operating income: 1,460 Thousand U.S. Dollars

(4) Time of the share acquisition

January 17, 2017

(5) Number of shares to be acquired, acquisition price and percentage of ownership after acquisition of shares

1) Number of shares owned before acquisition: 0 shares

2) Number of shares to be acquired: common stock: 23,006,790 shares (Number of voting rights: 23,006,790)

3) Acquisition price of Rubicon’s common stock: 75,000 Thousand U.S. Dollars

4) Number of shares owned after acquisition of common stock: 23,006,790 shares

(Number of voting rights: 23,006,790, ownership ratio of voting rights: 100%)

(6) Fund procurement and payment methods

The acquisition will be fully funded with Takara Bio Group’s own funds.